Clinical trial
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
NCT00026520 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00026520 |
|---|---|
| Title | Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma |
| Official title | Evaluation of Interferon Alpha-2b and Thalidomide in Patients With Disseminated Malignant Melanoma, Phase II |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, thalidomide |
| Start date | Nov 1, 2001 |
| Completion | Apr 1, 2006 |
| First posted | Jun 25, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: